Drugs and their level of understanding will enhance pharmacokinetics. Unfortunately, their level of understanding will not be helped by some of the errors that have crept into this article.

For drugs which display first order kinetics the plasma half life and clearance are constant irrespective of the amount of drug available in the body for elimination. This is in contrast with a drug which displays zero order kinetics, where the clearance falls with increasing concentration as the elimination process becomes saturated. The definition of the volume of distribution of a drug is not, as stated in this paper, the amount of drug in the body available for elimination, but is the theoretical volume of fluid in which the drug is distributed if it existed in the same concentration elsewhere as it does in the plasma. This would be given by dividing the total amount of drug in the body by the plasma concentration. It is also incorrect to state that if the volume of distribution is reduced the peak plasma concentration will increase. This will be the case if the distribution process is rapid, but another major determinant of peak plasma concentration is the rate of absorption, and for a drug which is rapidly absorbed but slowly distributed, such as digoxin, volume of distribution will have a negligible effect on peak plasma concentration.

Finally, I find the term 'accumulation', as used here, confusing. Accumulation is not a phenomenon that depends upon the property of a drug, nor are there drugs which accumulate and drugs which do not accumulate. It depends upon the relation between the half life of the drug and the dosing interval and, by definition, accumulation occurs if the drug is given at a dosage interval of less than the half life.

The prevalence of patients whose accumulation of piroxicam will occur and what we are speaking about in elderly subjects is relatively greater accumulation. It must also be stated that accumulation is not, in itself, a bad thing but is in fact necessary to produce fairly stable plasma concentrations.

T PULLAR
Clinical Pharmacology and Rheumatology
Department of Medicine
General Infirmary
Leeds LS1 3EX

Cryptosporidial enteritis complicated by conjunctivitis
Sir: Shepherd et al recently reported two children with cryptosporidial enteritis complicated by reactive arthritis.1

A 13 year old girl with a past history of epilepsy, asthma, and hypothyroidism presented with a second week of profuse watery diarrhoea, colicky lower abdominal pains, lethargy, nausea, vomiting, scattered arthralgic and myalgic pains. She also had conjunctivitis in both eyes. The child was admitted and stool examination showed oocysts of Cryptosporidia spp. No other pathogens were uncovered, and she eventually made a spontaneous recovery; her conjunctivitis settled.

Reiter's syndrome may follow urethral infection or gastroenteritis, and the clinical features of the condition—namely, arthritis, conjunctivitis and urethritis, or gastroenteritis, are well known. Shepherd et al described two female paediatric cases (and referred to one adult male case described by others) where cryptosporidiosis was complicated by reactive arthritis; all these subjects were evidently immunocompetent. In addition, two potentially relevant cases positive for antibody to HIV have been described, one being a 27 year old homosexual man with diarrhoea, urethritis, conjunctivitis, arthritis, and cryptosporidial enteritis, and the other a 4 year old child (sex unknown) with cryptosporidiosis who developed conjunctivitis as part of a more profound systemic illness (which was subsequently diagnosed as measles).2

Our patient had recurrent watery diarrhoea and scattered arthralgic and myalgic pains associated with her gastroenteric illness; accordingly, although the pathogenesis of cryptosporidial enteritis in immunocompetent subjects remains poorly understood, it is feasible that Reiter's syndrome may represent a potential clinical consequence of the condition. It may be pertinent to note that unlike the almost total male exclusivity of Reiter's syndrome associated with urethritis, among cases of Reiter's syndrome associated with gastroenteritis (of whatever underlying cause) a much larger proportion occur in women.3 In addition, the syndrome has been reported occurring in sexually inactive children.4


SIR: Dr Pullar's points are well taken, though such a detailed pharmacokinetic exposition was not available to me within the constraints on space imposed by a brief review article. Matters were rendered more ambiguous by the incorrect positioning of the term 'volume of distribution' whilst events, from my own transcribing error and for which I apologise. This allowed false conclusions to be drawn.

I remain less confused than Dr Pullar by the term 'accumulation', though accept that this

enjoys a precise definition and that 'relatively greater accumulation' is a more accurate description of what was being discussed. Although agreeing that accumulation may be beneficial in producing stable plasma concentrations, this benefit can only be reaped safely if the drug is relatively free from side effects.

H A BIRD
The University of Leeds
Royal Bath Hospital
Cornwall Road
Hermagor
North Yorkshire
HG1 2PS


Raised plasma concentrations of endothelin-1 in systemic lupus erythematosus
Sir: Endothelin-1 is a newly described vasoconstrictor peptide produced and secreted by vascular endothelial cells.1 It has potent and long-lasting vasoconstrictive action and it may participate in the pathogenesis of hypertension and vascular spasm. High plasma concentrations of endothelin-1 have been reported in acute and chronic renal failure,2 atherosclerosis,3 and in myoccardial infarction.4–6

Systemic lupus erythematosus is commonly associated with nephritis, hypertension, peripheral vasculitis, and vasospastic diseases like malignant hypertension and Raynaud's phenomenon.7

In this study we measured venous plasma concentrations of endothelin-1 in 28 young female patients with systemic lupus erythematosus. All patients met at least four of the American Rheumatism Association's diagnostic criteria8 for systemic lupus erythematosus and were randomly chosen from a cohort of patients with systemic lupus erythematosus interviewed about their obstetric histories. Control subjects were selected from the male laboratory personnel. Plasma endothelin-1 concentrations were measured by a specific radioimmunoassay.4 The endothelin-1 antiserum used showed less than 0.1% cross reaction with big endothelin-1 and its fragment 22–38, and fragment 171–201 of preproendothelin-1. It cross reacted 100% with endothelin-2 and -3. Plasma endothelin-1, when analysed by high performance liquid chromatography, and endothelin-1 in immune precipitations, coeluted with synthetic endothelin-1. No other peaks of immunoreactivity were detected. The small amount of endothelin-1 in plasma did not allow testing for bioactivity. The findings in this endogenous peptide correlated with the clinical picture of systemic lupus erythematosus. We also measured anti-cardiolipin antibodies by an enzyme linked immunosorbent assay (ELISA). Lupus nephritis was verified by biopsy in 13 of the 15 patients, who at some time of their disease had had proteinuria of more than 5 g/day.

The distribution of biopsy findings according to WHO classification was as follows: type II thrombocytopenia and anti-ribonucleoprotein antibodies, type III drug induced thrombocytopenia, and type V one patient. Biopsy was not done in two patients. Statistical analysis was by the x2 method.

Plasma concentrations of endothelin-1 were raised in 23 of 28 patients with systemic lupus erythematosus as compared with the normal range (mean 2 (SD)) in 66 healthy subjects (table). Raised plasma endothelin-1 concentrations (pg/ml) were found in patients with nephritis (p<0.05) but did not correlate significantly with hypertension, Raynaud's phenomenon (present in 8/28 (29%) of patients), migraine (present in 6/28 (21%)), thrombocytopenic events, from my own transcribing error and for which I apologise. This allowed false conclusions to be drawn.

I remain less confused than Dr Pullar by the term 'accumulation', though accept that this

enjoys a precise definition and that 'relatively greater accumulation' is a more accurate description of what was being discussed. Although agreeing that accumulation may be beneficial in producing stable plasma concentrations, this benefit can only be reaped safely if the drug is relatively free from side effects.

H A BIRD
The University of Leeds
Royal Bath Hospital
Cornwall Road
Hermagor
North Yorkshire
HG1 2PS


LETTERS TO THE EDITOR